The most frequent mutations associated with rifampin and isoniazid resistance in
Tuberculosis (TB) still remains a major public health problem worldwide, especially in developing countries, with approximately eight million new infections and 2,5 million deaths per year (Dye et al. 1999) .
Since the resurgence of TB in the mid-1980s, an increasing number of drug-resistant (DR) Mycobacterium tuberculosis strains have developed throughout the world. The last decade has seen a particular increase in the occurrence of drug-resistant (DR-TB) and multi-DR strains [resistant to rifampin (Rif r ) and isoniazid (Iso r ) MDR-TB]. This resurgence has threatened short-course TB chemotherapy (WHO 2006) and is a growing global public health concern (Zumia & Grange 2001) . A major point of concern is that patients infected with DR-TB and multidrug-resistant TB (MDR-TB) strains are more difficult to treat and are more likely to remain as sources of infection for longer periods of time than patients with drug-susceptible strains (Zumia & Grange 2001) .
Drug resistance in M. tuberculosis is caused by mutations in conserved regions of the genome (Musser 1995 , Zhang & Telenti 2000 . Rif r is mainly caused by mutations in the β subunit of RNA polymerase, which is encoded by the rpoB gene. More than 95% of resistant strains harbour mutations within the Rifampin Resistant Determining Region (RRDR), an 81-bp hot-spot region (codons 507 to 533) of rpoB. In contrast, Iso r is controlled by a more complex genetic system that involves more than one gene, but the most common mutations are associated with katG and the mabA-inhA intergenic region (Musser 1995 , Zhang & Telenti 2000 .
In 2006, the rates of morbidity and mortality of TB in Mexico was estimated to be 14 and 2.5 cases per 100,000 people, respectively. In the same year, the state of Veracruz, in the Southeast of Mexico, reported 1,800 TB cases resulting in 250 deaths among its population of seven million inhabitants; this state is considered one of the largest contributors of the disease. Information regarding the evolution of DR-TB and MDR-TB in Mexico is scarce, with the last survey from 1997 showing that 21% and 7% of isolates were DR-TB and MDR-TB, respectively (Granich et al. 2000) . In 2007, 541 DR-TB cases were reported in Mexico, with 105 (20%) originating in Veracruz, placing this region among the main sources of these isolates. Unfortunately, no official data regarding MDR-TB was recorded (Programa estatal de tuberculosis 2008). The 2008 DR-TB and MDR-TB survey will provide a better understanding of the extent of this health problem in Mexico (National Survey on TB drug resistance 2008).
The frequency of mutations related to rpoB and katG in DR-TB strains vary widely around the world (Zhang & Telenti 2000) . Unfortunately, information about the frequency and distribution of the mutations in DR-TB strains in Mexico is limited (Alvarado et al. 2001 , Bobadilla del Valle et al. 2001 , Viader-Salvado et al. 2003 , Ramaswamy et al. 2004 . Thus, we propose to explore the molecular patterns of mutations in rpoB and katG genes of sensitive and drug resistant mycobacteria strains obtained from patients experiencing pulmonary symptoms of TB. DNA purification and specie determination -Genomic DNA from each clinical strain was prepared using the sodium chloride, c-ethyl-trimethylammonium bromide and phenol-chloroform method (Sambrook et al. 1989) . Species determination was carried out in duplicate by multiplex PCR amplification of IS6110, 65kDa, DNAJ (Bahttacharya et al. 2003) and RFLP from hsp65 (Telenti et al. 1993) . Reference band patterns were generated us- Amplification of rpoB and katG genes -Multiplex PCR was carried out in 100 μL reactions containing 50 mM KCl, 10 mM Tris (pH 8.0), 25 mM MgCl 2 , 10 mM deoxynucleoside 3' -phosphates (dNTPs), 2U Taq polymerase (Promega Madison, WI), 5 nM of an rpoB primer set, 4 nM of a katG primer set (Table I ) and 300 ng chromosomal DNA from each isolate. Samples were then subjected to one cycle at 95°C for 30 s, followed by 35 cycles at 94°C for 1 min, 65°C for 1 min, 72°C for 1.3 min and a final elongation cycle at 72°C for 5 min. PCR products were electrophoretically separated on a 2% agarose gel containing ethidium bromide and examined for the presence of the 280-bp and 580-bp bands indicative of the rpoB and katG products, respectively. The amplicons of interest were excised from the agarose gel and purified using the mini-elute gel extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
MATERIALS And METHOdS

Clinical samples and
DNA sequencing and analysis -The PCR primer sets (Table I ) amplify the 81-bp hot-spot region of rpoB, including codon 531 and codons 240-390 of katG, including codon 315. DNA sequencing was carried out in an ABI Prism 7500 capillary sequencer (Applied Biosystems, Foster City, CA, USA) employing a Big Dye terminator cycle sequencing kit (Applied Biosystems). DNA sequence analysis and comparisons of rpoB and katG were carried out with Chromas V.2.3 and ClustalV programs. The rpoB and katG sequences from M. tuberculosis H37Rv strain, GenBank accession reference numbers 888164 and X68801, respectively, were used to construct the alignment.
RESULTS
Characterization of clinical isolates -Twenty five clinical isolates were collected from February-July, 2007. Following the Telenti protocol (Telenti et al. 1993) , all were shown to have the band profile from the Mycobacterium complex. However, according to the Bahttacharya procedure (Bahttacharya et al. 2003) , isolate 67 did not fit into any category and isolate 497 displayed the M. bovis profile band. Biochemical probes were inconclusive, therefore both isolates were denominated Mycobacterium spp.
Five of the isolates (20%) were drug susceptible, 20 (80%) were resistant to at least one drug and 11 (44%) were resistant to four or more drugs. Fifteen isolates (60%) were Rif r , 17 (68%) were Iso r and 15 (60%) were Rif r and Iso r , that is, MDR (Table II) . Identical results were obtained with duplicate samples.
Mutations in rpoB and katG genes -Mutations in the hot-spot of rpoB were detected in 14 (93%) isolates, with each also displaying MDR. No mutations were observed in the Mycobacterium spp isolate (IN: 497). Eleven isolates showed only one mutation (IN: 11, 12, 53, 54, 63, 78, 109, 123, 444, 481, 535) Despite the narrow window of specimen collection and the scarcity of clinical isolates, we were able to analyze 20 DR-TB isolates, which approximates the 15% of the DR-TB isolates reported annually by the public health services of Veracruz. It is important to mention that 18 isolates (90%) were resistant to more than one drug and 15 (75%) were MDR-TB. These percentages contrast with the 1997 national surveillance on DR-TB, in which prevalences of 21.5% for one drug, 7.4% for MDR and 2.6% for five or more drugs were recorded (Granich et al. 2000) . The 2008 DR-TB national surveillance will help to obtain a clearer understanding of the true status and evolution of this public health problem (NSTBDR 2008) . Most of the mutations reported worldwide in the rpoB gene of Mycobacterium occur at codons 526 and 531 (Huang et al. 2002 , Sajduda et al. 2004 , Hillemann et al. 2005 , Höfling et al. 2005 ; indeed, mutations at these sites explain 85-95% of Rif r cases. However, these mutations only explain 65% of our Rif r isolates: 18% (n = 3) for 526 and 47% (n = 7) for 531. Several mutations found in our isolates are in agreement with previous reports of isolates from the north and centre of Mexico (Alvarado et al. 2001 , Bobadilla del Valle et al. 2001 , Viader-Salvado et al. 2003 , Ramaswamy et al. 2004 ) and other countries (Huang et al. 2002 , Sajduda et al. 2004 , Hillemann et al. 2005 , Höfling et al. 2005 . However, five novel mutations were found in Rif r isolates. Two of these resulted in a single nucleotide change, 510 (CAG-AAG, Q→K) and 524 (TTG-TCG, L→S), while three mutations contained double nucleotide changes, 517 (CAG-CTA, Q→L), 521 (CTG-CCT, L→P) and 526 (CAC-TGC, H→C). Additionally, two new mutations were observed in Rif s isolates, 528 (CGC-CCT, R→P) and 522 (TCG-TTC, S→F). The effect of these new mutations on protein functionality should be carefully evaluated.
According to Telenti's procedure (Telenti et al. 1993) , two isolates were shown to pertain to the M. tuberculosis complex. However, using Bahttacharya's assay (Bahttacharya et al. 2003) , isolate 67 did not fit into any category and isolate 497 exhibited an M. bovis profile. Some doubts arise from the latter assay given that both isolates grew properly in Löwestein-Jensen medium and no pyrazinamide resistance was detected. Moreover, biochemical probe analysis for both isolates were inconclusive. Furthermore, both isolates have specific drug resistance profiles. Isolate 67 showed a unique combined resistance to streptomycin and ethambutol while isolate 497 presented resistance to streptomycin, Iso and Rif. Analysis of the katG gene displayed two mutations, one at codon 315 and the second at codon 331. This last mutation was not observed in the remainder of the analyzed isolates. On the other hand, no mutations were observed in the rpoB gene. A similar result was previously reported in other Rif r isolates, with the mutations being located outside the RRDR (Heep et al. 2000 (Heep et al. , 2001 . Currently, we are working on identifying mutations in the complete rpoB gene from isolate 497. In order to obtain the correct species assignment, we are attempting to sequence the 16S rDNA gene of both atypical isolates.
Isolate 30 was reported as Rif s , however, a mutation was found at codon 522 (TCG-TTC, S→F). A similar mutation at this codon (S→L) was recently reported to correlate with a low level of resistance in clinical isolates and to be associated with a bacterial fitness deficit (Mariam et al. 2004 , Huitric et al. 2006 . Thus, this isolate could help in understanding the real value of this codon change in the biology of Mycobacterium and the sensitivity of the BACTEC system for the diagnosis of DR-TB. At present, we are determining the minimal inhibitory concentration of this isolate via the microplate alamar blue assay.
Concerning Iso
r resistance, mutation at codon 315 in katG explains only 52% (n = 9) of the 17 Iso r isolates analyzed. Hence, the frequency of this mutation may vary according to geographical area, even within a single country. In agreement with our data, others have reported that 64% of 70 isolates from India have this mutation (Nusrath et al. 2008) , as well as 62% of 79 isolates from Spain (Torres et al. 2002) and 53% of 67 isolates from the North of Mexico (Viader-Salvadó et al. 2003) . In partial agreement, others have found that 67% of 37 isolates from the North of Mexico have this mutation (Ramaswamy et al. 2004) , as well as 69% of 105 isolates from Poland (Sajduda et al. 2004 ) and 72% of 69 isolates from Brazil (Silva et al. 2003) . Finally, in another study, no variability was observed in the mutation frequency of codon 315; a mutation was observed in 100% of 92 isolates from Kazahastan, Belarus (Hilleman et al. 2005) . Hence, this mutation needs to be analyzed in a local context, not by international comparison.
It is possible that mutations in other genomic regions, such as the mabA-inhA intergenic region, the inhA and the kasA genes (Musser 1995 , Zhang & Telenti 2000 , may contribute significantly to Iso r resistance in the isolates from the southern part of the country. It is interesting to note that six additional mutations were identified in the katG region of Iso r isolates. Three of these mutations, one at codon 328 and two nonsense mutations at codons 312 and 316, have been previously reported (Nusrath et al. 2008 , Bostanabad et al. 2008 , while three others were novel observations (codons 311, 318 and 331). However, all isolates contain mutations to codon 315, except for a nonsense mutation at codon 335 in an Iso s isolate (IN: 524) and at codon 328 in an Iso r isolate (IN: 328) . Thus, the role these mutations might play in inducing conformational changes in katG or inhibiting Iso r binding, resulting in Iso r resistance, is uncertain and needs to be evaluated in detail.
Understanding the nature and frequency of mutations associated with DR-TB in different settings is important for the development of genetic-based assays useful for the detection of drug resistance on a large-scale (Pai et al. 2006) . In this study, mutations in rpoB codon 531 and in katG codon 315 were identified only in 47% of the Rif r and 63% of the Iso r collected isolates, respectively. Furthermore, each isolate showed a particular mutational pattern. These data need to be considered if a genetic-based diagnosis of DR-TB is to be developed for the region. Additionally, these data are indicative of a high heterogeneity of DR-TB isolates present among the population, possibly exacerbated by inappropriate clinical management of patients. Genotyping and epidemiological studies are in progress in order to confirm this hypothesis.
In conclusion, this is, to our knowledge, the first report of mutations at katG and rpoB genes from sensitive and drug resistant Mycobacterium isolates from the South of Mexico, a regional source of a large number of immigrant workers within the United States of America. At present, we are collecting additional DR-TB isolates and increasing the number of genes that will be analyzed in order to identify mutations associated with first and second line drugs. This information will help us to cre-ate a better and more detailed description of the DR-TB isolates moving among the population and to improve molecular strategies for their diagnosis and control.
